Newsbenzinga
MAIA Biotechnology Says Enrollment In Phase 3 THIO-104 Lung Cancer Trial Of Ateganosine Reaches 65, Targets Over 100 By Year-End
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…